Pyoderma gangrenosum in acute myeloid leukaemia during immunosuppression.
We describe a patient who developed pyoderma gangrenosum during the remission phase of acute myeloid leukaemia whilst receiving maintenance therapy with methotrexate and 6-mercaptopurine. The spontaneous resolution of these skin lesions following discontinuation of chemotherapy suggests that these drugs may be of major significance in the aetiology of pyoderma gangrenosum. Nevertheless, 27 months later, a relapse of the leukaemia followed. Although pyoderma gangrenosum occurred during clinical remission, we cannot rule out a synergism of leukaemia and chemotherapy in its pathogenesis.
van de Kerkhof
P C
PC
Department of Dermatology, University of Nijmegen, The Netherlands.
de Vaan
G A
GA
Holland
R
R
D000328:Adult; D005734:Gangrene / Q000209:etiology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007951:Leukemia, Myeloid / Q000188:drug therapy; D008297:Male; D015122:Mercaptopurine / Q000009:adverse effects*; D008727:Methotrexate / Q000009:adverse effects*; D011711:Pyoderma / Q000209:etiology*
D015122:Mercaptopurine; D008727:Methotrexate